Saturday, October 31, 2026

Energy Markets

3 articles

Talen Energy's $500M Gas Bet Joins Global Shift to Bridge Fuel Strategy

Talen Energy's $500M Gas Bet Joins Global Shift to Bridge Fuel Strategy

Talen Energy acquired 2.6 GW of US natural gas capacity for $500 million on January 15, 2026, mirroring global utility bets on gas as transition fuel. The deal tests whether gas assets command 20%+ premiums over coal and renewables portfolios as European and Asian markets face similar coal-to-gas transition pressures.

ViaNews Editorial Team•
Permian Pipeline to Add 2.5 Bcf/d Gulf Coast Capacity by 2028 as Global LNG Demand Reshapes U.S. Gas Markets

Permian Pipeline to Add 2.5 Bcf/d Gulf Coast Capacity by 2028 as Global LNG Demand Reshapes U.S. Gas Markets

The Blackcomb Pipeline will deliver 2.5 billion cubic feet per day from Texas's Permian Basin to Gulf Coast export terminals by December 2028, connecting landlocked U.S. shale gas to international LNG markets. The project addresses bottlenecks that have kept Permian prices $1+ below benchmark Henry Hub, as U.S. export capacity expands to 14.7 Bcf/d to supply Europe and Asia. Midstream firms with fee-based contracts stand to benefit as global demand pulls more American gas overseas.

ViaNews Editorial Team•
U.S. Gulf Coast Adds 400,000 Barrel-Per-Day LPG Terminal Targeting Asian Markets

U.S. Gulf Coast Adds 400,000 Barrel-Per-Day LPG Terminal Targeting Asian Markets

A 400,000 barrel-per-day LPG export terminal will open on the U.S. Gulf Coast in 2028, adding 20% capacity to American liquefied petroleum gas infrastructure. The facility targets Asian petrochemical demand and European heating markets, where U.S. suppliers compete with Middle Eastern exporters for a growing 115 million ton global trade.

ViaNews Editorial Team•
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com